Answers are grounded in this paper and cite their sources.
Demonstrates improved access to innovative BTC treatments in Europe, indicating a shift in outcomes for patients.
The incidence of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), is increasing globally.1 This trend is especially notable among younger individuals in Europe and imposes a significant socio-economic burden on society.1,2 Most patients with BTC are diagnosed at an advanced stage or have comorbidities, making them ineligible for curative-intent surgery and associated with shorter survival.3 However, recent advances in BTC treatments, such as combining immune checkpoint inhibitors (ICIs) with standard-of-care chemotherapy (i.e., cisplatin plus gemcitabine) and the use of molecularly-targeted drugs, along with the development of intra-arterial therapies for some liver-limited or -predominant iCCA cases, have led to improved outcomes while maintaining BTC patients’ quality of life.
No takes yet. Share an insight, caveat, or question.
Turpin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: